Table 3.
Association of demographic, clinical, therapeutic parameters and PROs with health risk perception, stress and loneliness
| How dangerous… | How stressed… | How lonely… | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| beta | 95% CI | p value | betaST | beta | 95% CI | p value | betaST | beta | 95% CI | p value | betaST | |
| Female | 0.20 | -0.27; 0.66 | 0.403 | 0.03 | 0.13 | -0.40; 0.66 | 0.625 | 0.02 | 0.66 | 0.22; 1.10 | 0.003 | 0.12 |
| Age | -0.02 | -0.13; 0.10 | 0.742 | -0,01 | 0.09 | -0.04; 0.22 | 0.174 | 0.06 | 0.00 | -0.11; 0.10 | 0.935 | 0.01 |
| JIA | (ref) | (ref) | (ref) | |||||||||
| SLE | 1.84 | 1.00; 2.68 | < 0.001 | 0.18 | 0.49 | -0.49; 1.46 | 0.328 | 0.04 | 0.02 | -0.78; 0.82 | 0.953 | 0.01 |
| JDM | 0.37 | -1.25; 2.00 | 0.651 | 0.02 | 0.02 | -1.86; 1.91 | 0.980 | 0.01 | -1.13 | -2.68; 0.42 | 0.151 | -0.06 |
| PhGA | -0.14 | -0.27; 0.00 | 0.054 | -0.08 | -0.03 | -0.19; 0.13 | 0.732 | -0.02 | 0.05 | -0.08; 0.18 | 0.453 | 0.03 |
| MTX | 0.92 | 0.44; 1.40 | < 0.001 | 0.16 | 0.45 | -0.10; 1.00 | 0.109 | 0.07 | 0.16 | -0.29; 0.61 | 0.498 | 0.03 |
| bDMARD | 0.54 | 0.06; 1.01 | 0.027 | 0.09 | -0.16 | -0.71; 0.39 | 0.567 | -0.02 | -0.10 | -0.55; 0.35 | 0.651 | -0.02 |
| PGA | 0.17 | 0.07; 0.27 | 0.001 | 0.15 | 0.22 | 0.11; 0.34 | < 0.001 | 0.18 | 0.10 | 0.01; 0.19 | 0.045 | 0.09 |
| CHAQ | 0.85 | 0.30; 1.40 | 0.002 | 0.14 | 0.75 | 0.13; 1.38 | 0.019 | 0.11 | 1.04 | 0.52; 1.55 | < 0.001 | 0.19 |
betaST: standardized beta coefficient; JIA: Juvenile idiopathic arthritis; SLE: Systemic lupus erythematosus; JDM: Juvenile dermatomyositis; PhGA: Physician`s global assessment of disease activity; MTX: Methotrexate; bDMARD: Biologic disease modifying antirheumatic drug; PGA: Patient`s global assessment of health status; CHAQ: Child health assessment questionnaire